On 15 July 2025, Sino Biopharmaceutical Limited ("Sino Biopharm", 01177.HK) announced that its wholly owned subsidiary Chia Tai Pharmaceutical Investment (Beijing) Group Co., Ltd. (“Chia Tai Pharmaceutical”), LaNova Medicines Limited ("LaNova Medicines"), LaNova Medicines's shareholders, and other relevant parties entered into the Sale and Purchase Agreement. Subject to fulfillment of completion conditions and the price adjustment mechanism, Chia Tai Pharmaceutical will acquire LaNova Medicines's 95.09% equity interests for an initial consideration price of approximately US$950 million, excluding the cash of LaNova Medicines of approximately US$450 million, the net payment to be made by Chia Tai Pharmaceutical is approximately US$500 million. Chia Tai Pharmaceutical currently holds 4.91% equity interests in LaNova Medicines. Upon completion of the transaction, LaNova Medicines will become an indirect wholly owned subsidiary of Sino Biopharm.
Han Kun acted as legal counsel to Sino Biopharm in this transaction, providing comprehensive legal services. The Han Kun team was led by Yang (Aaron) Gu, with support from a diverse legal team comprising Cheng Chen, Ying Li, Tao Li, Shipo (Angus) Xie, Zhaojun (Sophie) Shi, Jia (Jenny) Li, Duzhiyun (Cathy) Zheng, Yu Tong, Na Wang, Xinghao (Randall) Wang, Fengmian Chen, Yunyao Wu, Yan Xu, Huayi Chen, Naifang Zhang and Shuwen Sun. The Han Kun team was deeply involved in all key stages of the transaction, including deal structuring, legal due diligence, drafting, revising and negotiating transaction documents. With expertise across life sciences and healthcare, regulatory, mergers and acquisitions, capital market, antitrust, and intellectual property, the Han Kun team delivered comprehensive legal support to the clients. This demonstrated Han Kun's outstanding capabilities in handling complex transactions in the life sciences and healthcare sector.
About Sino Biopharm
Sino Biopharm is a leading innovative and R&D-driven pharmaceutical conglomerate in China. It prides itself on a fully-integrated industrial chain, covering various R&D platforms, intelligent production operations and a formidable sales system. Its products including biopharmaceutical and chemical medicines enjoy an advantageous position in a host of therapeutic areas, such as oncology, liver diseases, respiratory diseases and surgery/analgesia.
Chia Tai Pharmaceutical is a wholly owned subsidiary of Sino Biopharm. It is principally engaged in investment activities and investment holding in the PRC.
About LaNova Medicines
LaNova Medicines is a biopharmaceutical company incorporated in the PRC with limited liability. Focusing on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment, and based on its self-developed GPCR and multi-transmembrane protein target antibody discovery platforms, LaNova Medicines is committed to the research and development of bio-innovative drugs with "first-in-class" and "best-in-class" development potential.
Han Kun's Life Sciences and Healthcare Practice
Han Kun is widely recognized and well-known for its practice in life sciences and healthcare. In relevant practice areas, we have been continuously ranked as a first-tier law firm by authoritative legal ranking agencies, including Chambers and Partners, The Legal 500, China Business Law Journal, Asialaw Profiles, etc. Han Kun is committed to providing clients with comprehensive legal services in life sciences and healthcare sector, including private equity and venture capital, mergers and acquisitions, onshore and offshore capital market, pharmaceutical license in/out and asset sale/purchase transactions, intellectual property, data protection, compliance and regulatory, and dispute resolution. Han Kun has a dedicated life sciences and healthcare team led by multiple partners and comprised of tens of specialist attorneys. Our partners on the team all have served a broad range of both domestic and foreign clients and developed a deep understanding of industry regulatory requirements and commercial course of dealings. Our associates on the team are graduates from top law schools both in China and abroad, all fluent in Chinese and English and equipped with excellent legal writing skills. Han Kun is well aware of the importance of professional legal services for life sciences and healthcare companies, especially those facing complex legal issues and therefore requiring special legal support. Clients value our teamwork as we fully leverage the expertise and experience of our professionals, all experts in their respective fields. Our goal is always to provide clients with thorough and practical solutions and high-quality legal services.
